Navigation Links
Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
Date:11/12/2012

ROCKVILLE, Md., Nov. 12, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the Company has entered into an agreement with Prev AbR LLC to acquire its clinical-stage and related beta-lactamase assets targeted for the prevention of Clostridium difficile (C. diff) infection, the leading cause of hospital acquired infections (HAI), that may occur secondary to treatment with antibiotics. The assets include a pre-Investigational New Drug (IND) package, Phase I and Phase II clinical data, manufacturing process data and all issued and pending U.S. and international patents intended to support an IND and Biologic License Application (BLA) with the FDA.

Beta-lactamase enzymes have the ability to degrade beta-lactam antibiotics that may be excreted into the GI tract. Beta-lactam antibiotics are a mainstay in hospital infection management and include both penicillins and cephalosporins. In 2011, an estimated 8.7 million Americans were administered intravenous beta-lactam antibiotics.[1] Utilizing the acquired biologic compounds, Synthetic Biologics intends to develop and commercialize a proprietary oral beta-lactamase enzyme product candidate, SYN-004. When co-administered with beta-lactam antibiotics in a hospital setting, it is expected that SYN-004 can preserve a patient's gastrointestinal (GI) microflora, thus preventing opportunistic C. diff infection (CDI).

C. diff Infection

In 2009, aggregate costs associated with CDI-related stays in the hospital were $8.2 billion in the U.S.[2] CDI is a global HAI in which the toxins produced by C. diff bacteria result in diarrhea (C. diff-associated diarrhea (CDAD)), and in the most serious cases, pseudomembranous colitis (erosion of the GI tract) that can lead to death. A major, unintended risk in the use of syste
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Taming mavericks: Stanford researchers use synthetic magnetism to control light
2. Synthetic Biologics Completes $10.8 Million Private Placement Financing
3. Synthetic Biologics Announces $10.8 Million Financing
4. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
5. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
6. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
7. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
8. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
11. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 The overall research objective ... sequencing trends and use. Most researchers outsource NGS ... to increase within the next 12 months. Data ... for purchasing sequencing instruments. Disease-related research is the ... RNA-Seq continues to surge, with half of the ...
(Date:9/30/2014)... Rainbow Scientific, Inc. (RSI), a North ... an online store to add customer convenience in ... and manufactured by Biological Industries, Inc. , Products ... Nutristem® serum-free, xeno-free reagents for human mesenchymal stem ... culture. , The online store also offers ...
(Date:9/30/2014)... Canada (PRWEB) September 30, 2014 Back in ... on 500 square feet. per employee, which included space for ... back then.” says Jeff Howell, partner at Nidea Corporate ... firm in Toronto. “By the year 2000, however, 250 ... now seeing that number come down to 175 to 225 ...
(Date:9/29/2014)... in Iraq and Afghanistan, more than 300,000 soldiers have ... caused by exposure to bomb blasts and in ... of traumatic brain injury can range from the mild, ... impairments in memory and cognition. , Since 2007, ... importance and complexity of this problem, and has made ...
Breaking Biology Technology:Global Next-generation Sequencing Trends 2Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... Va., Oct. 16 Varian Medical,Systems (NYSE: ... version of its market-leading,VariSeed(TM) brachytherapy seed planning ... allow greater visibility of the,treatment. "The ... the positions of,individual seeds in permanent seed ...
... Ranked 11th of the ,200 Best Small Companies In ... Inc.,(Nasdaq: ABAX ), a medical products company manufacturing ... chairman and chief executive officer, was named "Entrepreneur of,the ... issue. Also in that,issue, Abaxis was ranked eleventh of ...
... Novartis Takes Top Spot, Previously Held by GlaxoSmithKline ... 16 Thomson,Scientific, part of The Thomson Corporation ... of information solutions to the worldwide research and,business ... recent,quarterly review of scientific literature on drugs and ...
Cached Biology Technology:Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 2Varian Medical Systems Introduces New and Improved VariSeed(TM) 8.0 Software for Permanent Seed Prostate Brachytherapy Treatments 3Abaxis CEO Clint Severson Named 'Entrepreneur of the Year' by Forbes Magazine 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 2Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007 3
(Date:9/30/2014)... Journal of Medicine reports positive results of a ... the subset of lung cancer marked by rearrangement of ... patients with advanced non-small cell lung cancer testing positive ... percent, with 3 complete responses and 33 partial responses. ... the disease to resume its growth after being slowed ...
(Date:9/30/2014)... is available in German . ... the most expensive foods in the world. Because they grow ... But the distinctive smell of truffles is not only of ... under the direction of the Goethe University Frankfurt have discovered ... soil bacteria which are trapped inside truffle fruiting bodies. , ...
(Date:9/30/2014)... to using marijuana, new research, involving mice and published ... Journal of Leukocyte Biology , suggests that just ... should. That,s because a team of Italian scientists have ... long-term damage to the immune system. This damage may ... as multiple sclerosis, inflammatory bowel disease and rheumatoid arthritis ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2On the trail of the truffle flavor 2Adolescent exposure to thc may cause immune systems to go up in smoke 2
... An international team of researchers, including a University of ... giant cephalopod fossils discovered two years ago in England contain ... the melanin found in the ink sac of a modern-day ... May 21 edition of the journal Proceedings of the ...
... Stanford University School of Medicine, Stanford, California, has been honored ... her years of volunteer service to ASM. "For as long ... Baron has been the heart and soul of my profession," ... Development, North America, for bioMrieux, Inc., Durham, NC. ...
... by financial strategists to determine what shares to purchase to ... diversified portfolio of another kind -- land to be set ... Instead of plugging into the formula the data for ... Amy Ando and agricultural economist Mindy Mallory used the historical ...
Cached Biology News:Squid ink from Jurassic period identical to modern squid ink, U.Va. study shows 2Squid ink from Jurassic period identical to modern squid ink, U.Va. study shows 3The American Society for Microbiology honors Ellen Jo Baron 2The American Society for Microbiology honors Ellen Jo Baron 3Financial tool considered climate change uncertainty to select land for conservation 2Financial tool considered climate change uncertainty to select land for conservation 3
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
... - Fixation medium Reagent B - Permeabilisation ... fixing cells in suspension with Reagent A ... B. This procedure gives antibodies access to ... characteristics of the cells intact. Specific formulations ...
...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: